close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.657 -0.043 (-1.16%)
Streaming Delayed Price Updated: 12:06 PM EDT, Sep 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
News headline image
Can This Beaten-Down AI Stock Bounce Back in 2026? ↗
It might take a while for this AI company to prove its worth, if it ever does so. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 AI Stocks to Buy in 2026, and 1 to Avoid ↗
Some AI-focused companies are not worth the trouble. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution
In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance
In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗
These two companies have very different risk-reward profiles. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Cathie Wood’s Strategic Pivot: Ark Invest Trims Tesla Holdings to Fuel AI and Crypto Bets Ahead of 2026
In a move that has captured the attention of Wall Street as the year draws to a close, Cathie Wood’s Ark Invest has executed a series of significant sales of Tesla, Inc. (NASDAQ: TSLA) stock throughout... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…
Via AB Newswire
Topics Artificial Intelligence
Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗
Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals Stock Is Soaring Today: Here&#39;s Why ↗
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. 
Via Benzinga
News headline image
Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today ↗
Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Jim Cramer: This Health Care Stock Has Been &#39;Horrendous&#39; ↗
Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and CEO transition. Stock has mixed technicals and death cross. 
Via Benzinga
News headline image
10 AI Stocks Worth Buying Right Now ↗
Building an artificial intelligence (AI) portfolio means looking beyond the obvious megacap names. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035
The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,... 
Via MarketMinute
Topics Artificial Intelligence Death Intellectual Property
News headline image
Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture
Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across... 
Via TokenRing AI
Topics Artificial Intelligence Economy Emissions
News headline image
Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
popEVE AI: Harvard-Developed Model Set to Revolutionize Rare Disease Diagnosis and Drug Discovery
Cambridge, MA & Barcelona, Spain – November 25, 2025 – A groundbreaking artificial intelligence model, popEVE, developed by a collaborative team of researchers from Harvard Medical School and the... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗
Getting in on the ground floor would be great, but only if there's massive upside ahead for the company. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is Recursion Pharmaceuticals a Meme Stock? ↗
The answer seems straightforward enough. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
From MarketNewsUpdates.com
Via GlobeNewswire
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock ↗
Recursion is about to go toe-to-toe with the largest healthcare company. 
Via The Motley Fool
Topics Animal Testing Artificial Intelligence
News headline image
AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures
A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change Intellectual Property
News headline image
Nvidia's AI Reign: A $5 Trillion Bellwether Shaping Wall Street's Fortunes
Nvidia's (NASDAQ: NVDA) recent stock performance has been a whirlwind of soaring highs and sharp corrections, acting as a potent barometer for the broader Wall Street landscape as of November 11, 2025.... 
Via MarketMinute
Topics Artificial Intelligence Economy Law Enforcement
News headline image
Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway ↗
Recursion's Q3 2025 results show a major revenue miss and widening loss, but the company highlights strong partnerships and a cash runway into 2027. 
Via Chartmill
News headline image
Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.